雅培日前举办了第七届雅培科技日暨进博会预展。从全球首创到中国首发,从展台走进临床和患者,进博会持续释放的溢出效应,雅培全球创新成果在中国不断落地。在今年的科技日上,雅培提前揭秘了今年参展进博会的重磅展品和亮点活动。
作为植入式心脏起搏器首创者,雅培在提升心律失常的诊断效率和治疗质量方面坚持创新。自2022年起,用于治疗心动过缓的雅培AVEIR VR单腔植入式无导线心脏起搏器通过“进博之门”开启了精彩的“中国之旅”,并于今年在中国成功获批上市并完成首批植入手术。
今年进博会上,AVEIR DR双腔植入式无导线心脏起搏器也将亮相,作为全球首款真正实现同步的双腔无线起搏器,通过雅培特有的i2i通讯技术能够实现右心房和右心室两个设备间的互联通信及真正的双腔无线起搏。
此外,雅培打造的瞬感系列血糖监测体系覆盖了从个人到医院的数字化解决方案。在科技日现场,雅培提前揭晓了即将在进博会上市的瞬感2持续葡萄糖监测系统,不必指尖采血,通过传感器和手机应用程序,可实时查看葡萄糖水平,还新增了蓝牙传输和可选高低血糖警报功能,稳准兼备守护血糖健康。
据悉,每年的进博会是雅培全方位展现涵盖诊断、医疗器械、营养品和药品等领域的前沿科技和创新成果的重要契机。今年除了重磅展品外,雅培还将在进博会期间通过主题沙龙、健康科普等丰富的展台活动。
(文章来源:广州日报)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.